News Article
The 7TH ANNUAL MIRACLES FOR MYELOMA 5K RUN/WALK will take place on Saturday, September 21, 2019. Last year, at the 6th Annual Miracles for Myeloma Run/Walk, over $80,000 was raised in pursuit of the cure for Multiple Myeloma, and a Senior Brian D. Novis Research Grant was awarded by the…
Page
Name: Brian G.M, Durie, MDBirth: Scotland, 1942Death: Scotland, 2025POSITIONS AND TITLES HELDInternational Myeloma Foundation (IMF)Co-Founder and Board MemberCedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses just how close we are to discovering a method of preventing both MGUS, and the transition from MGUS to active myeloma.BOTTOM LINE:There is a high likelihood that in the coming years, both the development MGUS and the transition…
Page
To prevent multiple myeloma, scientists are investigating what causes the disease. Recent evidence has linked myeloma with exposure to toxic chemicals. Several viruses have been identified as potential triggers. We also now know there is a 2- to 4-…
Videos
.button {
background-color: #4CAF50;
border: none;
color: white;
padding: 15px 25px;
text-align: center;
font-size: 18px;
font-weight: bold;
cursor: pointer;
}
.button:hover {
background-color: green;
}
Double-click on the image above to view a replay of…
Videos
In this week’s video, Dr. Durie explains how a previously ineffective drug can work in a different combination therapy.BOTTOM LINE:Yes, a drug used in a previous combination that is no longer working can be used effectively as part of another combination therapy.Transcript:This…
Page
The International Myeloma Foundation (IMF) is firmly committed to compliance with the Americans with Disabilities Act. As part of this committment, the IMF has taken steps to make our website as accessible as possible for all users. We continue to work diligently with…
Page
(function(t,e,s,o){var n,c,l;t.SMCX=t.SMCX||[],e.getElementById(o)||(n=e.getElementsByTagName(s),c=n[n.length-1],l=e.createElement(s),l.type="text/javascript",l.async=!0,l.id=o,l.src=["https:"===location.protocol?"https://":"http://","widget.surveymonkey.com/collect/website/js/…
Page
People with multiple myeloma are living longer with improved treatments. Thus, proper health maintenance practices are increasingly important. Provided are resources and information to assist multiple myeloma health care providers in navigating patients’ long-term health care.
Important…
Page
Myeloma patients should be considered for clinical trials during all phases of treatment. The novel agents available for myeloma have all been developed through the clinical trials process, substantially increasing survival of myeloma patients over a short period of time.…
Page
The myeloma patient will require support to alleviate the physical and emotional impact of living with this illness. The IMF encourages early use of supportive care measures, which are just as important as initiating therapy. This section covers care guidelines for managing symptoms and side…
Page
Shared Decision Making
Deciding that treatment is necessary is the most pressing initial decision post-diagnosis. Since all treatments have side effects, treatment must be medically necessary and the benefits of treatment must outweigh unwanted side effects. The provider and the patient should…
Page
In 2015, the revised international staging system (R-ISS) from the International Myeloma Working Group (IMWG) was published, which provides the most up-to-date tool for stratifying multiple myeloma patient risk based on prognosis. On October 2020, the…
Page
The progression of myeloma varies greatly from person to person. Accurate diagnosis and risk stratification are essential in…
Page
Empower Yourself
To make good decisions about your care with your healthcare team, learn as much as you can about myeloma and its treatments. You can do so by accessing IMF publications here or reaching out to an IMF InfoLine at 1-800-452-CURE (2873) or at …
Event
.button {
background-color: #207588;
border: none;
color: #FFFFFF;
text-align: center;
font-size: 16px;
font-weight: 600;
padding-top: 10px;
padding-right: 20px;
padding-bottom: 7.5px;
padding-left: 20px;
cursor: pointer;
border-radius: 50px;
text-decoration…
Page
The IMF Leads the Charge to Find a Cure for MyelomaThe International Myeloma Foundation is committed to the search for a cure or cures. It is central to our mission: Accelerating the prevention and cure of myeloma and improving the quality of life for patients and families.
News Article
On Wednesday, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (XPOVIO™) in combination with dexamethasone for the treatment of relapsed/…
Videos
In this week's video, Dr. Durie discusses what effect a new treatment can have on your myeloma protein levels, and when it can be time to…
News Article
The FDA has approved the combination of daratumumab (Darzalex) with lenalidomide (Revlimid) and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).
Videos
In this week’s video, Dr. Brian G.M. Durie discusses how denosumab works against RANK ligand and what happens when the treatment is suddenly stopped.
BOTTOM LINE:
Take caution when stopping denosumab. Talk to your doctor about the use of a bridging treatment such as…
Page
Diagnosis
It is important to recognize the early warning signs and diagnose myeloma as early as possible. Myeloma can be slow-moving or more aggressive.
A skilled myeloma specialist…
Audio
As Mary Ford explains, her story began on Sunday evening at the grocery store. She leaned into a refrigerated section at the store, sneezed, and felt intense pain in her back. A Registered Nurse, Mary was at work the next day and mentioned to her colleague that this sneeze had given her so much…
Audio
At 52 years old, Paula Nemet was diagnosed with multiple myeloma. During a routine check-up, her doctor suspected that she had myeloma. A week later, she started treatment. Paula found comfort in her local support group and created lifelong relationships. Her support group leader became a mentor to…
Audio
Diagnosed in 2006, Daniel Scott's oncologist at the time told him, "You have one-and-half to two years to live." As he says, "Here I am. It's 2019." Listen to his myeloma journey, from a rocky diagnosis to a successful transplant followed by relapse. Today, he takes part in the…
Audio
When Anne Mackey was diagnosed with multiple myeloma, she rallied a team of medical experts to guide her through her journey. She was resolved not to let her diagnosis become her whole life. The Jacksonville support group showed her that there is a world of people with a myeloma diagnosis, living…
News Article
On Wednesday, June 12, 2019, the U.S. Senate unanimously approved a bill to extend disability benefits to veterans who served on ships off the coast of Vietnam, known as Blue Water Navy Vietnam Veterans. This move signals the end of a decades-long fight for these former sailors and Marines to…
News Article
On June 12, 2019, the International Myeloma Foundation’s Advocacy department led a group of cancer advocates to Capitol Hill as a part of Coalition to Improve Access to Cancer Care (CIACC) efforts to increase support for the Cancer Drug Parity Act of 2019.
The advocates met with…
Videos
IMF Co-founders Receive a Joint Honorary Doctorate in Recognition of Scientific Excellence
Watch the ceremony at Vrije Universiteit Brussel (VUB) in Brussels
In a ceremony on April 2, 2019 dedicated to “the beauty, the power, and the wisdom of science,” International Myeloma Foundation…
Spreading Public Awareness at the Dr. Charles R. Drew Blood Drive and Health Fair in Compton, Calif.
News Article
On Saturday, June 8, 2019, at Compton’s 13th Annual Building Better Communities Through Better Health Fair, the International Myeloma Foundation was front and center doing what it does best: bringing education and awareness to communities who do not necessarily have access to it.…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses how these factors—M-protein spike, the percentage of bone marrow plasma cells, and the serum free light ratio—help determine if SMM will advance to active myeloma.
BOTTOM LINE:
The BOTTOM LINE: Refer to the “…
Videos
Dr. S. Vincent Rajkumar on an International Study of the t(11;14) Abnormality in Multiple Myeloma Patients
Multiple myeloma (MM) is a heterogeneous disease with varying survival outcomes depending on the presence of certain genetic abnormalities. Common abnormalities include
…
Page
.resp-container {
position: relative;
overflow: hidden;
padding-top: 56.25%;
}
.resp-iframe {
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
border: 0;
}
International Myeloma Foundation (the “Foundation”), will conduct its…
Videos
Dr. María V. Mateos on an Updated Risk Stratification Model for Smoldering Multiple Myeloma
The diagnostic criteria for multiple myeloma (MM) were revised in 2014, recategorizing ultra-high risk (i.e., 80% at two years) as active myeloma requiring therapy. The removal of patients at the highest…
Event
.button {
background-color: #4CAF50;
border: none;
color: white;
padding: 15px 25px;
text-align: center;
font-size: 18px;
font-weight: bold;
cursor: pointer;
}
.button:hover {
background-color: green;
}
Learn more about current trends in myeloma treatment and…
News Article
The International Myeloma Foundation (IMF) will host the 10th Annual International Myeloma Working Group (IMWG) Summit from June 10–12 in Amsterdam. More than 100 of the world’s top myeloma experts will attend the 2019 Summit, which convenes on the…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses how the MRD test can be used to predict long-term remission.BOTTOM LINE:Discuss with your doctor the sensitivity of the MRD test, and where you are in your course of treatment. Repeat tests to ensure there is sustained MRD…
News Article
Los Angeles, CA, May 23, 2019—The International Myeloma Foundation (IMF) will honor two outstanding multiple myeloma specialists whose work has significantly improved the lives of patients at a ceremony June 11 in Amsterdam.
The IMF, the first and largest organization…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses MGUS and the medical issues that can occur with the diagnosis.
BOTTOM LINE:
MGUS has a 1% per year risk of becoming myeloma. MGUS patients may develop other medical issues other than myeloma. Always discuss this…
Page
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian G.M. Durie’s Week in Review blog. The leading myeloma expert and IMF Chief Scientific Officer drills down on a wide range of topics – from the…
Page
The 2018 Annual Summit of the IMF’s Global Myeloma Action Network (GMAN) convened on June 17–19 in Stockholm, Sweden. The event brought together 35 advocacy organizations representing 25 countries from Asia, Australia, Europe, and Latin and North America. The contributions of Dr. Brian G.M. Durie (…
News Article
New policies are being put into place by many health plans called “copayment accumulator programs” or “accumulator adjustment programs.” Prior to these new policies, when a patient used a copay assistance card or other manufacturer assistance, the payment or discount credited by that manufacturer…